Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
In this application note, we demonstrate how the C
The Nobel Prize in Physiology or Medicine awarded
In today’s rapidly evolving bioprocessing landsc
Alembic Pharmaceutica
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Mi
Roche Holding AG’s risdiplam showed significant improvement in survival and motor milestones in a clinical trial for infants with type 1 spinal muscular atrophy (SMA), the Swiss drugmaker said on Tuesday.
Location of neurons affected by spinal muscular atrophy in the spinal cord
The Firefish part 2 study met its primary endpoint by demonstrating a significant increase in motor milestones in infants aged 1-7 months after 12 months of treatment, it said. Safety was consistent with the safety profile observed to date and no new safety signals were identified, it added.